PCSK9 inhibition produces incremental benefits on coronary disease progression in patients treated with statins.
The task force finalizes recommendations for statin therapy among adults between 40 and 75 years of age.
Statin-based therapy had a smaller effect in reducing major vascular events in patients with advanced chronic kidney disease.
Researchers found that dietary changes, other medications, and surgery can also lower cardiovascular risk.
Results from a study presented at ACC in Chicago suggest that statins can be more widely used in patients considered to be intermediate risk for cardiovascular disease.
Is the real benefit of statins their anti-inflammatory benefits?
Statin use in co-infected patients showed a slowed progression of liver disease, according to a study conducted at the Johns Hopkins Moore Clinic for HIV Care.
For older adults at risk for heart attack or stroke, statin use is cost effective in 48% to 67% of patients.
While statins may decrease aggression in men, they appear to increase it in postmenopausal women.
Patients with subclinical hypothyroidism who take statins have an increased risk of developing diabetes.
Patients with life-limiting illnesses often take statins, and discontinuing these can increase quality of life.
Clinicians should clearly explain the risks and benefits to patients beginning statin therapy.
Under the pediatric guidelines, 2.5% of the patients surveyed would qualify for statin treatment while only 0.4% would qualify under the adult guidelines.
A patient's gender does not affect the efficacy of statin therapy for major vascular events.
There was no difference overall in the incidence with different statins, but high-dose atorvastatin was associated with increased hospitalization.
A new study indicated that older patients with predialysis chronic kidney disease should take statins.
Small but statistically significant improvements in adherence were seen among intervention participants.
Compared with patients who had not taken statins, those who had were less likely to develop diabetic neuropathy by 34%, diabetic retinopathy by 40%, and gangrene by 12%.
More than 40% of those taking high-dose statins don't reach LDL-C target of <70 mg/dL
Increase largely driven by eligibility of adults aged 60 years and older without cardiovascular disease in the primary prevention setting.
A systematic review of available evidence uncovered no association between the use of statins and adverse cognitive outcomes.
Diabetes risk only increased in those with one or more major risk factors.
The FDA warns of a small increased risk for elevated blood glucose levels and possible problems with transient memory and cognition with statin use.
A large, long-term project by the Heart Protection Study Collaborative Group showed that statin therapy increasingly reduced heart attack, stroke, and other vascular disease as treatment continued, and that these benefits persisted for several years after treatment had stopped.
Is there evidence showing that women taking statins saw little improvement in their lipid levels?
Statins given before or during hospitalization reduced mortality in adults with influenza.
Clinical practice in patients with moderate or high cardiovascular risk or existing cardiovascular disease should not change.